REGENXBIO Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) announced that it intends to conduct an underwritten public offering of $100 million of its common stock, subject to market and other conditions. The company noted there is no assurance regarding completion, timing, actual size or final terms of the offering.
According to REGENXBIO, the company also plans to grant underwriters a 30-day option to purchase up to 15% additional common shares. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers. The offering will be made under an effective Form S-3 shelf registration statement filed in November 2025.
Positive
- Announced intention for underwritten common stock offering of approximately $100 million
- Uses an effective Form S-3 shelf registration to expedite capital access
- Includes 30-day underwriter option for up to 15% additional shares, potentially increasing proceeds
Negative
- Planned issuance of $100 million in common stock adds to shares outstanding
- Final size, timing and terms of the offering remain uncertain and subject to market conditions
News Explained
The proposed financing could dilute existing holders, but its final economic size remains unpriced until the prospectus supplement.
The July 16, 2026 release remains a proposed, not completed, offering. If it occurs, REGENXBIO would issue common shares, reducing existing holders’ percentage ownership absent offsetting changes.
In an underwritten offering, investment banks buy securities from the issuer for resale, and fees reduce net proceeds below the gross amount. The effective Form S-3 supplies registration capacity rather than itself selling shares.
The release provides no final price, share count, fees, or net proceeds; it says those terms will be disclosed in a final prospectus supplement. On the Q1 cash-use basis, the proposed
The next specified resolution point is the final prospectus supplement, which will state the offering’s final size, price, and fees.
Sources and calculations
- July 16, 2026 REGENXBIO proposed public offering release (2026-07-16)
- Dilution definition (2026-07-14)
- Underwritten offering definition (2026-07-14)
- Form S-3 purpose (2026-07-14)
- Prospectus supplement purpose (2026-07-14)
- REGENXBIO first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $100,000,000 / ($76,186,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $15,229,000 / ($76,186,000 / 90) = [object Object]
Market reaction after $100 million common stock offering: RGNX -11.70% in the Jul 17 session
In the Jul 17 session, RGNX declined 11.70%, reflecting a significant negative market reaction. Argus tracked a trough of -35.3% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Milestone payment & trial | Positive | +12.9% | First patient dosed in NAAVIGATE DR trial triggering $100M AbbVie milestone. |
| Jun 24 | Clinical program update | Positive | +0.2% | Completion of RGX-202 confirmatory study supporting planned BLA submission. |
| Jun 22 | FDA alignment update | Positive | +18.2% | Agreement with FDA on NAVSUNLI BLA resubmission path with expedited review. |
| May 18 | Conference participation | Neutral | -1.1% | Announcement of participation in upcoming investor healthcare conferences. |
| May 14 | 1Q26 earnings report | Negative | -37.8% | Q1 2026 results with sharp revenue drop and significant net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory milestones have generally produced aligned gains, while the last earnings report coincided with a sharp selloff.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
joint book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers of the offering.
The securities described above are being offered by REGENXBIO pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the "SEC") on November 26, 2025 (File No. 333-291816) and declared effective on December 12, 2025. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, whether REGENXBIO will be able to raise capital through its proposed offering of common stock. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025 and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (the "SEC") and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ZOLGENSMA® is a registered trademark of Novartis. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302827988.html
SOURCE REGENXBIO Inc.